Modulari-T

We teach your immune system to attack and cure cancer

Y CombinatorWinter 2023ActiveHealthcareTherapeuticsGene TherapyCell TherapySynthetic BiologyBiotech

What they do

Problem

Current cell and gene therapies lack efficient, programmable ways to reprogram immune and stem cells to sense their environment and effectively treat diseases like cancer.

Solution

A platform of synthetic genes that can be inserted into cells to reprogram their sensing and behavior, enabling engineered immune cells to recognize and kill cancer and engineered stem cells to regenerate tissue.

Who it's for

Biotechnology and pharmaceutical companies and cell-therapy developers engineering immune or stem cells for therapeutic use.

Founders

David White

Founder

David is the CEO and cofounder of Modulari-T. His expertise spans multiple areas and he is driven by a passion for pushing the boundaries of technology. During his PhD he discovered how protein receptors form complex structures that allow them to alter cells’ behavior. He then took this knowledge and the novel technology that was developed to build Modulari-T. When he’s not thinking up a new way to engineer cells he can be spotted biking or running up a mountain.

Stephanie Mok

Founder

Co-founder and COO at Modulari-T. PhD in chemical engineering. Technical background in synthetic biology, advanced 3D cell culture systems, and biomaterials in the context of the cellular cancer microenvironment. Fascinated by the innovations cell-based therapies, food products, and the scale up of their manufacturing. Gave the unconference talk "Lessons learned and mistakes made growing the world's hottest peppers".